Ategra Capital Management’s GSK GSK Stock Holding History

Ategra Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,593	Closed	-$304K	–	101
2022 Q2	$304K	Sell	5,593 -1,058	-16%	-$58.4K	0.16%	79
2022 Q1	$362K	Sell	6,651 -713	-10%	-$38.7K	0.16%	85
2021 Q4	$406K	Sell	7,364 -380	-5%	-$19.8K	0.18%	83
2021 Q3	$370K	Sell	7,744 -1,261	-14%	-$63.3K	0.18%	83
2021 Q2	$448K	Sell	9,005 -138	-2%	-$6.63K	0.22%	77
2021 Q1	$408K	Buy	9,143 +57	+0.6%	+$2.59K	0.23%	75
2020 Q4	$418K	Buy	9,086 +3,086	+51%	+$142K	0.29%	63
2020 Q3	$282K	Buy	6,000 +808	+16%	+$40.5K	0.25%	69
2020 Q2	$265K	Hold	5,192	–	–	0.25%	72
2020 Q1	$246K	Hold	5,192	–	–	0.29%	63
2019 Q4	$305K	Hold	5,192	–	–	0.26%	71
2019 Q3	$277K	Sell	5,192 -618	-11%	-$31.8K	0.25%	76
2019 Q2	$291K	Sell	5,810 -263	-4%	-$13.2K	0.27%	81
2019 Q1	$317K	Buy	+6,073	New	+$303K	0.31%	72

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ategra Capital Management's GSK Position: Q3 2022 in Review

Ategra Capital Management sold out of GSK (GSK) in Q3 2022, closing a stake of 5,593 shares — an estimated $304K sold.

Ategra Capital Management first reported a position in GSK in Q1 2019 and held it in 14 quarters. The position peaked at $448K in Q2 2021. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Ategra Capital Management reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Ategra Capital Management sold 5,593 GSK shares in Q3 2022, an estimated $304K.
Ategra Capital Management first reported a position in GSK in Q1 2019 and held it in 14 quarters.
Ategra Capital Management's GSK position peaked at $448K in Q2 2021.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Ategra Capital Management's 13F filing for Q3 2022, filed 14 Feb 2025.